Intracavitary irradiation of endometrial carcinoma stage I by a high dose-rate afterloading technique

Sorbe, Bengt; Frankendal, B.; Risberg, Bjørn

doi:10.1016/0090-8258(89)90539-8

Cited by 21 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For a small subset (3.5-9.0 %) of patients, surgery is not feasible due to the presence of medical comorbidities and advanced age [58,59]. Radiotherapy alone, frequently incorporating brachytherapy, has been shown to yield favorable outcomes in early-stage disease [60][61][62][63][64][65][66]. In the largest series to date with 280 patients treated using conventional intracavitary brachytherapy, 5-year local control rates for clinical stage IA and stage IB patients were 86.0 and 68.8 % [60].…”

Section: Medically Inoperable Treatment Paradigmmentioning

confidence: 99%

Current Concepts in Radiation Therapy for Early-Stage Endometrial Cancer

Gill

Minkoff

Beriwal

2015

Indian J Gynecol Oncolog

View full text Add to dashboard Cite

Purpose The present article aims to review current management for early-stage endometrioid carcinomas with a specific focus on adjuvant radiotherapy. Methods A comprehensive literature review was conducted regarding management of early-stage endometrioidtype endometrial cancers. Abstracted information included risk of relapse, treatment approach, and morbidity from treatment. Results A majority of low-risk patients are safely managed with observation, with vaginal cuff brachytherapy (VCBT) reserved for those with multiple other risk factors. Intermediate-risk patients are a heterogeneous group with a variable definition; previous trials have established that VCBT alone is suitable for most patients to avoid morbidity of pelvic external beam radiotherapy (EBRT). Highand high-intermediate risk patients warrant pelvic EBRT ± VCBT with or without sequential chemotherapy. Continued controversy exists regarding the optimal VCBT fractionation regimen, with suggestion that higher dose/ fraction regimens may lead to increased vaginal toxicity. Intensity-modulated radiotherapy is being investigated in an effort to reduce late toxicities. Advanced brachytherapy techniques such as image-guided brachytherapy have improved treatment of salvage and medically inoperable patients.Conclusions Identification of risk groups and toxicity reduction through either appropriate radiotherapy techniques or advanced techniques has enabled optimization of adjuvant management for early-stage endometrial cancer.

show abstract

Section: Medically Inoperable Treatment Paradigmmentioning

confidence: 99%

Current Concepts in Radiation Therapy for Early-Stage Endometrial Cancer

Gill

Minkoff

Beriwal

2015

Indian J Gynecol Oncolog

View full text Add to dashboard Cite

show abstract

“…The dose per fraction has ranged from 5 Gy to 12 Gy, and four to six fractions are commonly employed. [24], [25], [26] If EBRT is added dose and/or then dose per fraction is reduced. The ABS-suggested doses for HDR brachytherapy alone or in combination with 45 Gy EBRT are given in Table 4.4.…”

Section: Carcinoma Of the Endometriummentioning

confidence: 99%

“…When patients are treated with high doses per fraction, the toxicity is higher (about 7%). [24] Table 3.2. American Brachytherapy Society suggested doses of high-dose-rate (HDR) brachytherapy alone or in combination with external beam radiation therapy (EBRT) to be used for adjuvant treatment of post-operative endometrial cancer [6] EBRT *HDR doses are specified at 2 cm from the midpoint of the intrauterine sources…”

Section: Carcinoma Of the Endometriummentioning

confidence: 99%

Effect of pFNA internal fixation of senile fracture in maxillofacial injuries

Shahabaz¹,

Afzal²

2021

SPR

View full text Add to dashboard Cite

A technique of radiation therapy delivery in which the radioactive sources are placed very close or even inside the target volume is called Brachytherapy (BT). Brachytherapy is a type of radiation therapy. It destroys cancer cells by making it hard for them to multiply. In this technique, a radiation source is placed directly into or near a tumour. High dose-rate brachytherapy is also known as HDR brachytherapy, or temporary brachytherapy. It is a type of internal radiotherapy. HDR was developed to reduce the risk of cancer recurrence while shortening the amount of time it takes to get radiation treatment. HDR also limits the dose of radiation (associated side effects) to surrounding normal tissue. The important benefits of HDR brachytherapy include extremely precise radiation therapy delivered internally, used alone or after surgery to help prevent cancer recurrence, convenient treatments that are usually pain-free, and a reduction in the risk of common short- and long-term side effects. Currently, tumour dose, as well as doses of the surrounding normal structures, can be evaluated accurately, and high-dose-rate brachytherapy enables three-dimensional image guidance. The biological disadvantages of high-dose-rate were overcome by fractional irradiation. In the definitive radiation therapy of cervical cancer, high-dose-rate brachytherapy is most necessary. Most patients feel little discomfort during brachytherapy. There is no residual radioactivity when the treatment is completed. A patient may be able to go home shortly after the procedure, resuming his normal activities with few restrictions. An advantage of brachytherapy is to deliver a high dose to the tumour during treatment and save the surrounding normal tissues. High-dose-rate (HDR) brachytherapy has great promise with respect to proper case selection and delivery technique because it eliminates radiation exposure, can be performed on an outpatient basis and allows short treatment times. Additionally, by varying the dwell time at each dwell position, the use of a single-stepping source allows optimization of dose distribution. As the short treatment times do not allow any time for correction of errors, and mistakes can result in harm to patients, so the treatments must be executed carefully by using HDR brachytherapy. Refinements will occur primarily in the integration of imaging (computed tomography, magnetic resonance imaging, intraoperative ultrasonography) and optimization of dose distribution and it is expected that the use of HDR brachytherapy will greatly expand over the next decade. Various factors in the development of well-controlled randomized trials addressing issues of efficacy, quality of life, toxicity and costs-versus-benefits will ultimately define the role of HDR brachytherapy in the therapeutic armamentarium. Surrounding healthy tissues are not affected by the radiation due to the ability to target radiation therapy at high dose rates directly to the tumour. Treatment to be delivered as an outpatient in as few as one to five sessions is also allowed by this targeted high dose approach. HDR brachytherapy is the most precision radiation therapy, even better than carbon ion therapy. At the time of invasive placement of the radiation source into the tumour area, brachytherapy requires the skills and techniques of radiation oncologists.

show abstract

High-Dose-Rate Brachytherapy for Medically Inoperable Stage I Endometrial Cancer

Nguyen¹,

Petereit²

1998

Gynecologic Oncology

View full text Add to dashboard Cite

Intracavitary irradiation of endometrial carcinoma stage I by a high dose-rate afterloading technique

Cited by 21 publications

References 44 publications

Current Concepts in Radiation Therapy for Early-Stage Endometrial Cancer

Current Concepts in Radiation Therapy for Early-Stage Endometrial Cancer

Effect of pFNA internal fixation of senile fracture in maxillofacial injuries

High-Dose-Rate Brachytherapy for Medically Inoperable Stage I Endometrial Cancer

Contact Info

Product

Resources

About